Generate Biomedicines

Recent news

• Rating change
  H.C. Wainwright Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $16
  Market Newswire · 2026/4/13
• Rating change
  Guggenheim Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/6/25
• Rating change
  H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $25
  Market Newswire · 2026/5/8
• Rating change
  Analysts Offer Insights on NA Companies: Yesway Inc Class A (YSWY), Generate Biomedicines, Inc. (GENB) and SK Hynix Inc. Sponsored GDR (OtherHXSCL)
  TipRanks · 2026/6/25
• Rating change
  Goldman Sachs Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26
  Market Newswire · 2026/4/11
• Rating change
  Guggenheim Reaffirms Their Buy Rating on Generate Biomedicines, Inc. (GENB)
  TipRanks · 2026/6/15
• H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $30
  Market Newswire · 2026/8/28
• H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $30
  Market Newswire · 2026/10/5
• Analysts Offer Insights on NA Companies: Guidewire (GWRE) and Generate Biomedicines, Inc. (GENB)
  TipRanks · 2026/9/9
• Rating change
  Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $24
  Market Newswire · 2026/8/7
• Rating change
  Morgan Stanley Sticks to Its Buy Rating for Generate Biomedicines, Inc. (GENB)
  TipRanks · 2026/8/17
• Rating change
  Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $22
  Market Newswire · 2026/8/17
• Rating change
  H.C. Wainwright Maintains Generate Biomedicines(GENB.US) With Buy Rating, Maintains Target Price $25
  Market Newswire · 2026/8/7
• Rating change
  Guggenheim Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $30
  Market Newswire · 2026/3/25
• Rating change
  Piper Sandler Sticks to Their Buy Rating for Generate Biomedicines, Inc. (GENB)
  TipRanks · 2026/5/8
• Rating change
  Cantor Fitzgerald Initiates Generate Biomedicines(GENB.US) With Buy Rating
  Market Newswire · 2026/3/24
• Rating change
  Morgan Stanley Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $22
  Market Newswire · 2026/5/14
• Rating change
  Goldman Sachs Initiates Generate Biomedicines(GENB.US) With Buy Rating, Announces Target Price $26
  Market Newswire · 2026/3/25
• Analysts Are Bullish on Top NA Stocks: Generate Biomedicines, Inc. (GENB), Netskope, Inc. (NTSK)
  TipRanks · 2026/10/2
• Piper Sandler Maintains Generate Biomedicines(GENB.US) With Buy Rating, Raises Target Price to $26
  Market Newswire · 2026/10/2

Headlines are aggregated automatically and are not independently verified or edited by our team.